Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Navigating a 1E+60 Chemical Space of Peptide/Peptoid Oligomers

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Herein we report a virtual library of 1E+60 members, a common estimate for the total size of the drug‐like chemical space. The library is obtained from 100 commercially available peptide and peptoid building blocks assembled into linear or cyclic oligomers of up to 30 units, forming molecules within the size range of peptide drugs and potentially accessible by solid‐phase synthesis. We demonstrate ligand‐based virtual screening (LBVS) using the peptide design genetic algorithm (PDGA), which evolves a population of 50 members to resemble a given target molecule using molecular fingerprint similarity as fitness function. Target molecules are reached in less than 10,000 generations. Like in many journeys, the value of the chemical space journey using PDGA lies not in reaching the target but in the journey itself, here by encountering non‐obvious analogs. We also show that PDGA can be used to generate median molecules and analogs of non‐peptide target molecules.

          Abstract

          Herein we report a virtual library of 1E+60 members, a common estimate for the size of the drug‐like chemical space. The library consists of linear or cyclic oligomers forming molecules within the size range of peptide drugs. We demonstrate ligand‐based virtual screening using a genetic algorithm.

          Related collections

          Most cited references67

          • Record: found
          • Abstract: found
          • Article: not found

          Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.

          SUMMARYPolymyxins are well-established antibiotics that have recently regained significant interest as a consequence of the increasing incidence of infections due to multidrug-resistant Gram-negative bacteria. Colistin and polymyxin B are being seriously reconsidered as last-resort antibiotics in many areas where multidrug resistance is observed in clinical medicine. In parallel, the heavy use of polymyxins in veterinary medicine is currently being reconsidered due to increased reports of polymyxin-resistant bacteria. Susceptibility testing is challenging with polymyxins, and currently available techniques are presented here. Genotypic and phenotypic methods that provide relevant information for diagnostic laboratories are presented. This review also presents recent works in relation to recently identified mechanisms of polymyxin resistance, including chromosomally encoded resistance traits as well as the recently identified plasmid-encoded polymyxin resistance determinant MCR-1. Epidemiological features summarizing the current knowledge in that field are presented.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Ultra-large library docking for discovering new chemotypes

            Despite intense interest in expanding chemical space, libraries of hundreds-of-millions to billions of diverse molecules have remained inaccessible. Here, we investigate structure-based docking of 170 million make-on-demand compounds from 130 well-characterized reactions. The resulting library is diverse, representing over 10.7 million scaffolds otherwise unavailable. The library was docked against AmpC β-lactamase and the D4 dopamine receptor. From the top-ranking molecules, 44 and 549 were synthesized and tested, respectively. This revealed an unprecedented phenolate inhibitor of AmpC, which was optimized to 77 nM, the most potent non-covalent AmpC inhibitor known. Crystal structures of this and other new AmpC inhibitors confirmed the docking predictions. Against D4, hit rates fell monotonically with docking score, and a hit-rate vs. score curve predicted 453,000 D4 ligands in the library. Of 81 new chemotypes discovered, 30 were sub-micromolar, including a 180 pM sub-type selective agonist.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              The Discovery and Development of Liraglutide and Semaglutide

              The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects on glycemic control and body weight regulation, led to efforts to extend its half-life and make it therapeutically effective in people with type 2 diabetes (T2D). The development of short- and then long-acting GLP-1 receptor agonists (GLP-1RAs) followed. Our article charts the discovery and development of the long-acting GLP-1 analogs liraglutide and, subsequently, semaglutide. We examine the chemistry employed in designing liraglutide and semaglutide, the human and non-human studies used to investigate their cellular targets and pharmacological effects, and ongoing investigations into new applications and formulations of these drugs. Reversible binding to albumin was used for the systemic protraction of liraglutide and semaglutide, with optimal fatty acid and linker combinations identified to maximize albumin binding while maintaining GLP-1 receptor (GLP-1R) potency. GLP-1RAs mediate their effects via this receptor, which is expressed in the pancreas, gastrointestinal tract, heart, lungs, kidneys, and brain. GLP-1Rs in the pancreas and brain have been shown to account for the respective improvements in glycemic control and body weight that are evident with liraglutide and semaglutide. Both liraglutide and semaglutide also positively affect cardiovascular (CV) outcomes in individuals with T2D, although the precise mechanism is still being explored. Significant weight loss, through an effect to reduce energy intake, led to the approval of liraglutide (3.0 mg) for the treatment of obesity, an indication currently under investigation with semaglutide. Other ongoing investigations with semaglutide include the treatment of non-alcoholic fatty liver disease (NASH) and its use in an oral formulation for the treatment of T2D. In summary, rational design has led to the development of two long-acting GLP-1 analogs, liraglutide and semaglutide, that have made a vast contribution to the management of T2D in terms of improvements in glycemic control, body weight, blood pressure, lipids, beta-cell function, and CV outcomes. Furthermore, the development of an oral formulation for semaglutide may provide individuals with additional benefits in relation to treatment adherence. In addition to T2D, liraglutide is used in the treatment of obesity, while semaglutide is currently under investigation for use in obesity and NASH.
                Bookmark

                Author and article information

                Contributors
                jean-louis.reymond@unibe.ch
                Journal
                Mol Inform
                Mol Inform
                10.1002/(ISSN)1868-1751
                MINF
                Molecular Informatics
                John Wiley and Sons Inc. (Hoboken )
                1868-1743
                1868-1751
                10 October 2024
                January 2025
                : 44
                : 1 ( doiID: 10.1002/minf.v44.1 )
                : e202400186
                Affiliations
                [ 1 ] Department of Chemistry Biochemistry and Pharmaceutical Sciences University of Bern Freiestrasse 3 3012 Bern Switzerland
                Author information
                https://orcid.org/0000-0003-2724-2942
                Article
                MINF202400186
                10.1002/minf.202400186
                11733718
                39390672
                161aa317-4c47-454c-a6fe-596296ac3a0a
                © 2024 The Author(s). Molecular Informatics published by Wiley-VCH GmbH

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 21 August 2024
                : 31 May 2024
                : 27 August 2024
                Page count
                Figures: 7, Tables: 2, References: 72, Pages: 11, Words: 0
                Funding
                Funded by: Swiss National Science Foundation , doi 10.13039/501100001711;
                Award ID: 200020_178998
                Funded by: European Research Council , doi 10.13039/501100000781;
                Award ID: 885076
                Categories
                Research Article
                Research Article
                Custom metadata
                2.0
                January 2025
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.2 mode:remove_FC converted:15.01.2025

                Bioinformatics & Computational biology
                genetic algorithm,therapeutic peptides,chemical space,cheminformatics

                Comments

                Comment on this article